Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 5, 2026
- Adicet Bio reported that 50% of evaluable lupus nephritis patients achieved a complete renal response at 12 months. Third-quarter net loss was $18.9 million, while cash, cash equivalents and short-term investments totaled $100.9 million as of September 30, 2026.
- 10-Q report · filed Nov 5, 2026
- Adicet Bio, Inc. is advancing prula-cel toward pivotal lupus studies, but substantial doubt exists about continuing as a going concern; nine-month losses were $60.5 million and cash totaled $100.9 million.
The audio replay and transcript follow the call.